Home » Authors » Trista Morrison

Articles by Trista Morrison

Proacta Completes $35M Series B For Hypoxia Trials

Feb. 8, 2007

By Trista Morrison

Proacta Completes $35M Series B For Hypoxia Trials

Feb. 8, 2007

By Trista Morrison

Deal-Making Trend: M&A Activity Continues to Rise

Feb. 7, 2007

By Trista Morrison

Deal-Making Competition Is Up; Winners Offer More Than Money

Feb. 6, 2007

By Trista Morrison

Deal-Making Competition Is Up; Winners Offer More Than Money

Feb. 6, 2007

By Trista Morrison

Ligand Restructures To Focus On Early Pipeline, Royalties

Feb. 2, 2007

By Trista Morrison

Ligand Restructures To Focus On Early Pipeline, Royalties

Feb. 2, 2007

By Trista Morrison

Repros Therapeutics Raising $36M On Positive Interim Data

Feb. 1, 2007

By Trista Morrison

Repros Therapeutics Raising $36M On Positive Interim Data

Feb. 1, 2007

By Trista Morrison

Ception Closes $63M Series C For Anti-Inflammatory Trials

Jan. 31, 2007

By Trista Morrison

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 14, 2025.
European VCs optimistic for med-tech exit opportunities in 2025
BioWorld MedTech
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Feb. 14, 2025
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
BioWorld
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...